Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
– Transformational progress in 2022 marked by reprioritization of high-value neurology pipeline and validation of TRACER™ novel capsid platform through transactions with Pfizer and Novartis –
Related news for (VYGR)
- MoBot’s Stock Market Highlights – 06/02/25 09:00 AM
- Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference
- Voyager Therapeutics Announces Pricing of Public Offering
- Voyager Therapeutics Announces Proposed Public Offering
- Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference